• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health’s CEO Invited to Present at the 148th National Investment Banking Association Conference

Aug 30, 2022 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that the company’s CEO will present at the upcoming 148th National...

Tivic Health’s CEO Invited to Present at the 148th National Investment Banking Association Conference

Aug 30, 2022 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that the company’s CEO will present at the upcoming 148th National...

Tivic Health Reports Strong Growth in Second Quarter 2022 Financial Results

Aug 15, 2022 | Press Releases

265% growth in unit sales through direct-to-consumer channels, 97% overall revenue growth vs. Q2 2021 SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and...

Tivic Health Reports Strong Growth in Second Quarter 2022 Financial Results

Aug 15, 2022 | Press Releases

265% growth in unit sales through direct-to-consumer channels, 97% overall revenue growth vs. Q2 2021 SAN FRANCISCO – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and...

Tivic Health to Report Second Quarter 2022 Earnings on August 15 Via Conference Call and Webcast

Aug 10, 2022 | Press Releases

SAN FRANCISCO – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the second quarter of 2022 via...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.